Hainan province, China-based Sihuan Pharmaceutical has signed an agreement with the Indian pharma company Hetero Drugs.
According to a statement, the two companies will work on R&D, regulatory affairs, manufacturing and commercialization in China.
The areas of focus for the collaboration include cardiovascular diseases, central nervous system diseases and infections such as the 2019-nCoV infection, which is spreading fast in China and has been seen elsewhere.
A major HIV and oncology drug supplier, Hetero is no stranger to China.
In 2014, it formed a joint venture with Henan province-based drug maker Furen Group to sell oncology drugs in China.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.